Phase II
Dicerna Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced it has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA).
Now that Novartis has a competing therapy on the market for spinal muscular atrophy (SMA), Biogen is eager to show why it thinks its Spinraza (nusinersen) is superior.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.
Krystal Biotech, Inc. announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study.
Continuous Monitoring with Wearable Device Detected Distinct Pulse Wave Patterns in Obstructive Hypertrophic Cardiomyopathy Patients as Compared to Healthy Volunteers
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, announced that half of the patients have been enrolled and started the treatment in the company’s Phase II-study with the company’s product candidate LL-37 for treatment of venous leg ulcers.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
PRESS RELEASES